Codagenix, Inc. Codagenix, Inc., is developing live attenuated vaccines using a software-based genome design algorithm that relies on whole-genome synthesis and it is unlike previous vaccine platforms. The Codagenix approach re-codes the target pathogens' own genome to be translated slowly in host cells. This re-recoding results in vaccine strain that is highly attenuated,... Category(s): Technology Classifications > Therapeutics and Vaccines, Technology Classifications > Biological Materials, Technology Classifications > Drug Delivery, Technology Classifications > Viral Vectors, Campus > Stony Brook University